A nationwide questionnaire‐based surveillance on pediatric hereditary angioedema in Japan
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70077
Abstract
Background: Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent edema and abdominal/laryngeal attacks. However, the number of pediatric HAE cases is unknown. We aimed to assess the number of pediatric HAE and the actual status of pediatric HAE management in Japan. Methods: A mail questionnaire survey was conducted on 142 clinicians (representatives of institutes) with previous experience in HAE management. The survey items included the number of pediatric patients who were treated for HAE, history of attacks and its impact on quality of life, the presence of untested pediatric relatives of adult patients, and unmet needs. Results: In total, 69 representatives (49% of overall institutes) responded. Twenty‐five (36% of respondents) had experience in pediatric HAE management. The number of cases managed by individual faculties ranged from 1 to 6, and most physicians ( n = 16, 64% of faculties with patient(s)) reported the management of a single case only. There were 26 (8 male,16 female) patients with one or more attacks. Nineteen facilities (28% of respondents) reported one or more pediatric relative(s) of patients who were hesitant to screen. Further, physicians reported various unmet needs. Conclusions: Pediatric HAE is managed in many facilities in a dispersed manner. In some cases, the pediatric relatives of patients diagnosed with HAE did not undergo screening. This study identified unmet needs and challenges that reflect the absence of specialized pediatric management. Hence, the standardization of pediatric HAE management is an urgent concern in Japan.Keywords
Funding Information
- European Federation of Pharmaceutical Industries and Associations
- Japan Society for the Promotion of Science (JP 60749951)
This publication has 12 references indexed in Scilit:
- Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open‐label studyThe Journal of Dermatology, 2023
- Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 studyAllergology International, 2023
- The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and updateWorld Allergy Organization Journal, 2022
- The diagnosis and treatment of hereditary angioedema patients in Japan: A patient reported outcome surveyAllergology International, 2021
- Berotralstat: First ApprovalDrugs, 2021
- Survey of actual conditions of erythema marginatum as a prodromal symptom in Japanese patients with hereditary angioedemaWorld Allergy Organization Journal, 2021
- Hereditary angioedema: Repeated attacks in a 10‐year‐old boyPediatrics International, 2019
- Pediatric Use of a C1 Esterase Inhibitor Concentrate for Hereditary Angioedema: Findings from the International Berinert® (C1-INH) RegistryJournal of Allergy and Clinical Immunology, 2016
- Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in JapanAnnals of Allergy, Asthma & Immunology, 2015
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012